Navigation Links
Cytopia Lodges IND for JAK2 Inhibitor CYT387
Date:6/22/2009

MELBOURNE, Australia, June 22 /PRNewswire/ -- Cytopia Ltd (ASX: CYT) announced today that it has filed an Investigational New Drug Application (IND) with the US Food and Drug Administration (FDA) for its novel, potent orally active JAK2 inhibitor CYT387.

Following FDA review, the company intends to commence a Phase I/II trial for CYT387 in patients with myelofibrosis, a serious progressive and chronic condition where scar tissue develops in the bone marrow. CYT387 is expected to be the second Cytopia developed drug candidate in clinical studies and the first trialled in the United States, with the anticancer

vascular disrupting agent CYT997 now in Phase II clinical studies in Australia.

Over-activity of the JAK2 enzyme is implicated in a variety of haematological conditions known as the myeloproliferative disorders (MPDs). This suite of conditions includes myelofibrosis, polycythemia vera and essential thrombocythemia. Cytopia has demonstrated that CYT387 inhibits the overactive JAK2 enzyme in an invivo preclinical model and in cells from patients with MPDs. This data suggests that the compound may exert a profound effect on the human disease.

Myelofibrosis results in a compromised ability of patients to produce sufficient blood cells and a reliance on organs other than the bone marrow, including the liver and spleen, to produce cells. Typical symptoms include an enlarged spleen and progressive anemia and poor overall survival.

"The filing of an IND for CYT387 is the culmination of a comprehensive preclinical development effort by the Cytopia Drug Development team," said Mr Andrew Macdonald, CEO of Cytopia. "Our deep knowledge of the JAK2 target has been integral to the design of this drug and the program is significantly bolstered by the intellectual property we hold over the JAK2 target."

The clinical utility of CYT387 is also expected to have broader applicability
'/>"/>

SOURCE Cytopia Ltd.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine news :

1. Cytopia To Present Data on FMS Program With Anticancer Potential
2. Cytopia Commences Phase II Cancer Drug Study
3. Potent metastasis inhibitor identified
4. Small molecule inhibitor shows promise in trastuzumab-resistant metastatic breast cancer
5. Cylene to Announce New Data on Its First-in-Class Oral CK2 Inhibitor Against Cancer at BIO Conference
6. For the Treatment of Rheumatoid Arthritis, Market Share for TNF-alpha Inhibitors Will Decrease Through 2018
7. Video: Novartis Receives Approval From FDA to Market Prevacid(R) 24HR as First and Only OTC Proton Pump Inhibitor in Original Prescription Formulation
8. SCAI Statement on A National Study of the Effect of Individual Proton Pump Inhibitors on Cardiovascular Outcomes in Patients Treated with Clopidogrel Following Coronary Stenting: The Clopidogrel Medco Outcomes Study
9. Alseres and BioAxone Amend License Agreement for Cethrin(R) and Rho Inhibitor Technology
10. Potential lung disease biomarkers yield clues to COX-2 inhibitor side effects
11. Experimental insulin-like growth factor receptor inhibitor reduced pancreatic cancer growth
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... The Special Olympics Missouri State Summer Games will bring more ... Columbia. This state-level event takes place May 30-June 2, on ... and at Hickman High School and Town & Country Lanes. ... 7:30 p.m. Friday, May 30 with the Opening Ceremony. The ... of Athletes, the culmination of the statewide Law Enforcement Torch ...
(Date:5/21/2013)... significantly more likely than their normal-weight counterparts to ... disrupts continuity of care and leads to more ... , The practice of "doctor shopping" among overweight ... with the health care system, whether that be ... advice by providers, or improperly sized medical equipment ...
(Date:5/21/2013)... May 21, 2013 Children using ... Sophono, Inc., experience audiological results comparable to the ... many fewer complications, according to a new study. ... that Sophono’s abutment-free technology performs just as well ... with many fewer complications,” says Jim Kasic, president ...
(Date:5/21/2013)... 21 (HealthDay News) -- Urban elementary school children ... sleep problems and suffer academically, new research indicates. ... seven to nine, we found that compromised lung ... impaired academic performance," said study author Daphne ... behavior at Brown University,s Alpert Medical School in ...
(Date:5/21/2013)... Positively charged gold nanoparticles are usually toxic to ... nanoparticle toxicity. Mayo Clinic researchers found out why, ... against ovarian cancer cells. The discovery is detailed ... Journal of Biological Chemistry ., "This study identifies ... by preventing the cell death or apoptosis which ...
Breaking Medicine News(10 mins):Health News:Special Olympics Missouri Athletes Ready to Show Off Skills in Columbia 2Health News:Special Olympics Missouri Athletes Ready to Show Off Skills in Columbia 3Health News:'Doctor shopping' by obese patients negatively affects health 2Health News:'Doctor shopping' by obese patients negatively affects health 3Health News:Abutment-Free Sophono Systems Produce Comparable Study Results to Cochlear’s Baha Products, With Fewer Complications 2Health News:Abutment-Free Sophono Systems Produce Comparable Study Results to Cochlear’s Baha Products, With Fewer Complications 3Health News:Sleepless Nights May Hurt School Performance of Kids With Asthma 2Health News:Mayo Clinic: How gold nanoparticles can help fight ovarian cancer 2
... WM Healthcare Solutions, Inc. (WMHS), a subsidiary ... has purchased substantially all of the assets of ... pharmaceutical waste management consulting services to the U.S. ... other custom consulting services, in addition to the ...
... World Voice Day, April 16, 2009) NEW YORK, April 16 ... musical theater singers in the New York area received a ... cords in April at the second annual free Voice Screening ... Eye and Ear Infirmary and MusiCares, the charitable ...
... run the 2009 Bank of America Chicago Marathon on October 11th with ... is approaching, so please apply by April 20th, 2009 at www.ChristopherReeve.org/TeamReeve ... ... Chicago Chapter of the Christopher & Dana Reeve Foundation announces the ...
... Launches ORBIT, Open-Source Robotic Biorepository & Informatics Technology MILWAUKEE, April 15 , ... Informatics Technology, ... developing ... library of blood samples and privacy-protected ...
... 15 Fundacion Azteca in Mexico and,Fundacion Azteca ... join efforts to,commemorate the 50th Movimiento Azteca. ... conglomerate founded by entrepreneur Ricardo B. Salinas.,Through a ... and,funds to improve the well-being of both mother ...
... always been a brand about lifting spirits and lending their happy ... the brand,s 50th Anniversary celebration, nine celebrity mothers have united for ... Cause . The celebrity designers include: ... Paltrow, Catherine Bell, Elisabeth Hasselbeck and Garcelle Beauvais-Nilon . ...
Cached Medicine News:Health News:Waste Management Subsidiary Acquires PharmEcology(R) Associates, LLC 2Health News:Singers Hit High Notes in Free Voice Screening at The New York Eye and Ear Infirmary 2Health News:Attention Runners: Run the 2009 Bank of America Chicago Marathon with Team Reeve 2Health News:Attention Runners: Run the 2009 Bank of America Chicago Marathon with Team Reeve 3Health News:Fundacion Azteca and Fundacion Azteca America Present 50th Movimiento Azteca to Increase Awareness and Raise Funds for Prenatal and Natal Care 2Health News:Fundacion Azteca and Fundacion Azteca America Present 50th Movimiento Azteca to Increase Awareness and Raise Funds for Prenatal and Natal Care 3Health News:Lilly Pulitzer(R) Launches A Colorful Cause Celebrity Designed Collection for EBMRF 2
(Date:5/21/2013)... , May 21, 2013 Reportlinker.com ... is available in its catalogue: ... Reimbursement Scenario for Medical Devices in the ...   Changing Regulatory and ... US Market   ...
(Date:5/21/2013)... Calif. , May 21, 2013 /PRNewswire/ ... ), a specialty pharmaceutical company focused on ... for the treatment of acute and breakthrough ... in a placebo-controlled Phase 3 study of ... analgesia) System (NanoTab System), the primary efficacy ...
(Date:5/21/2013)... N.C. and HENDERSONVILLE, N.C. ... Medicare bidding procurement program for home medical equipment ... North Carolina to lay off employees ... the quality of service and products received by Medicare ... Under the defective and dangerous program, the Centers ...
Breaking Medicine Technology:Changing Regulatory and Reimbursement Scenario for Medical Devices in the US Market 2Changing Regulatory and Reimbursement Scenario for Medical Devices in the US Market 3Changing Regulatory and Reimbursement Scenario for Medical Devices in the US Market 4Top-line Data Demonstrate Primary Endpoint Achieved in Final Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Management of Post-Operative Pain 2Top-line Data Demonstrate Primary Endpoint Achieved in Final Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Management of Post-Operative Pain 3Top-line Data Demonstrate Primary Endpoint Achieved in Final Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Management of Post-Operative Pain 4Top-line Data Demonstrate Primary Endpoint Achieved in Final Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Management of Post-Operative Pain 5Top-line Data Demonstrate Primary Endpoint Achieved in Final Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Management of Post-Operative Pain 6Top-line Data Demonstrate Primary Endpoint Achieved in Final Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Management of Post-Operative Pain 7Top-line Data Demonstrate Primary Endpoint Achieved in Final Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Management of Post-Operative Pain 8Top-line Data Demonstrate Primary Endpoint Achieved in Final Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Management of Post-Operative Pain 9Top-line Data Demonstrate Primary Endpoint Achieved in Final Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Management of Post-Operative Pain 10North Carolina Business Owners At Risk Because Of Defective Medicare Bidding Program 2North Carolina Business Owners At Risk Because Of Defective Medicare Bidding Program 3North Carolina Business Owners At Risk Because Of Defective Medicare Bidding Program 4
... Dec. 22 Mylan Inc. (Nasdaq: MYL ) today ... approval from the U.S. Food and Drug Administration (FDA) under ... New Drug Application (NDA) for Efavirenz Tablets, 50 mg, 100 ... form were developed by Matrix for use in treating pediatric ...
... , , , , ... announced that it has entered into an agreement with Laboratoires ... lipase. , DSM has successfully completed process development and commenced ... and Phase I clinical needs. DSM BioSolutions manufactures the lipase ...
Cached Medicine Technology:Mylan Receives Tentative FDA Approval Under PEPFAR for Matrix Laboratories' New Drug Application (NDA) for Efavirenz Tablets 2DSM to Manufacture 'MS1819' Lipase Compound for Mayoly Spindler 2DSM to Manufacture 'MS1819' Lipase Compound for Mayoly Spindler 3DSM to Manufacture 'MS1819' Lipase Compound for Mayoly Spindler 4
Drugs of Abuse (DoA) Array is used for in-vitro diagnostic tests for the qualitative determination of the parent molecule and metabolites of drugs in human urine....
For use with catalog #0454....
For use with catalog #0454....
Immuno-turbidimetric Assay of D-Dimer by STA© Analyzers. Microlatex particles coated with two different mouse monoclonal anti-human D-Dimer antibodies....
Medicine Products: